Third, pharmacological inhibition of RIPK3 attenuated cardiomyocyte death and cardiac pathology in a mouse model of type-1 diabetes, indicating the potential of pharmacological inhibition of necroptosis signaling as a useful therapeutic intervention for cardiac complications of diabetes. Here, RIPK3 is linked to diabetes mellitus.